IL10 and in situ carcinoma: In people with CIS, low serum IL-10 levels were associated with a higher risk and shorter interval to second events and correlated with a significantly higher white blood cell count in cerebrospinal fluid (CSF), number of T2 lesions, and gadolinium-enhancing lesions at the baseline MRI [31].